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Contraception in the perimenopausal transition years is a very important aspect of women’s health, and it is the responsibility of 
all health care workers to discuss and render adequate counselling in this regard. Failure to do so can have serious health and 
mental consequences caused by unplanned pregnancies. There are a number of safe and effective options that one can offer 
these women. Most of these methods also have beneficial non-contraceptive properties.
Introduction
Falling pregnant in the perimenopausal 
years can potentially have a very det-
rimental effect on a woman’s physical 
as well as her mental health. Although 
some women do choose to be pregnant 
later in life, the vast majority of pregnan-
cies of women in their mid-forties are un-
planned, with termination of pregnancy 
rates as high as 60%.1 Pregnancy after 
the age of 35 years is also associated 
with increased maternal and foetal mor-
bidity. The risk for foetal aneuploidy 
is increased, as well as the spontane-
ous miscarriage rate.2,3 Maternal risks 
include increased risks of gestational 
diabetes, placenta previa, postpartum 
haemorrhage, malpresentations, op-
erative delivery and premature delivery. 
The risks for low birth weight as well as 
stillbirths are also increased.4
An unplanned pregnancy in a woman 
in her mid to late forties will also affect 
the rest of the family in many different 
ways. It impacts on the current and 
future financial situation, as well as on 
retirement planning.
It is thus obvious that the importance 
of proper contraception in this group of 
women should not be underestimated.
Physiology
The years prior to menopause are 
known as the perimenopausal transi-
tional years. This period is characterised 
by irregularity of menstrual cycles. The 
average age of onset is 46 years and 
average duration is 5years.5
Not only is there an accelerated loss 
of ovarian follicles during the perimeno-
pause, but there is also a decrease 
in the productive quality of the aging 
follicles. This leads to a decrease in 
levels of inhibin A and B, with a sub-
sequent rise in FSH levels, while LH 
levels remain unchanged and oestradiol 
levels are slightly elevated. This results 
initially in lengthening of the menstrual 
cycles, followed by prolonged periods 
of anovulation, subsequently causing 
abnormal vaginal bleeding. During this 
time occasional ovulation and corpus 
luteum function will occur, and that is 
the origin of the unexpected unplanned 
pregnancy.5,6
Contraceptive Options
Fortunately there is more than one 
option available regarding contracep-
tion for the perimenopausal woman. A 
detailed history and general as well as 
gynaecological examination is an es-
sential part of the consultation, as every 
woman needs to be assessed regarding 
risks as well as contra-indications. 
Oral Contraception
Combined oral contraceptives remain 
one of the best options in this group 
of patients. Not only is it very effective 
if used correctly, but it also provides 
well-known non-contraceptive benefits. 
These benefits include amongst others, 
lower risk of endometrial and ovarian 
cancer, reduction in menstrual blood 
loss, treatment of abnormal bleeding 
caused by anovulatory cycles and a 
decrease in dysmenorrhoea. 
After 12 months of use there is a 50% 
risk reduction of developing endometrial 
cancer, with maximum benefit after 3 
years of use. This protective effect 
remains for up to 20 years after discon-
tinuation of use. The risk reduction in 
developing epithelial ovarian cancer in 
women using oral contraception is 40%. 
After 10 years of use the risk reduction 
is 80%.7
Women in the perimenopausal tran-
sitional age are at higher risk of having 
co-morbidities such as hypertension, 
obesity, hyperlipidaemia and diabetes 
mellitus. Non smoking women with well 
controlled hypertension and diabetes 
can safely use low dose combined oral 
contraceptive preparations. In patients 
with hyperlipidaemia without vascular 
disease or very high levels of triglycer-
ides, low dose oral contraception is not 
contra-indicated. Healthy non-smoking 
obese patients can also use low dose 
oral contraceptives.
Women over the age of 35 years who 
smoke should not use combined oral 
contraceptives, because of the very high 
risk of myocardial infarction observed in 
this group of women. The incidence of 
myocardial infarction in non smoking 
women older than 35, using combined 
oral contraception, is 40 per 100000 
per year, compared to 485 per 100000 
per year in those over 35 years who 
are smokers.8 Other absolute contra-
indications to the use of combined oral 
contraception includes thromboembolic 
disorders, markedly impaired liver func-
tion, breast cancer, and undiagnosed 
abnormal vaginal bleeding.
It is safe for perimenopausal women 
to continue with low dose oral contra-
ceptives until age 50, at which time FSH 
levels are determined on day 7 of a pill-
free cycle. This is done every year and 
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when FSH is greater than 20 IU/L, the 
woman can be regarded as postmeno-
pausal.9 Hormone therapy should then 
be considered as per indication.
The progestin-only minipill is also 
an option for this group of women, 
especially women in which oestrogen 
intake is contra-indicated. Fecundity 
(the physiological ability to reproduce) 
in women in the perimenopausal transi-
tional years is markedly reduced, which 
increases the efficacy of the minipill. It 
also decreases abnormal bleeding due 
to anovulation.9
Injectable contraceptives
Depomedroxyprogesterone acetate has 
been well studied and is a very effec-
tive contraceptive. It is an option that 
can safely be used in perimenopausal 
women, especially in women where 
oestrogen is contra-indicated. Women 
with severe migraine, hypertryglyc-
eridaemia, thromboembolic disease or 
smokers can make use of this form of 
contraception. Side –effects include 
depression, headaches, and irregular 
vaginal bleeding.10 It can also be used 
until the age of 50 years, or until meno-
pausal symptoms develop. At the age of 
50, FSH levels can be measured yearly, 
even while the woman is on therapeutic 
levels, as progestin does not influence 
FSH levels.
Intra-uterine devices
Both the copper containing as well as 
the levonorgestrel intra-uterine devices 
are suitable for use by perimenopausal 
women. They are both safe and effective 
and they have very little side-effects and 
contra-indications. The levonorgestrel 
intra-uterine device is also registered 
for use in patients with menorrhagia, 
and the fact that many women using 
this device experience amenorrhea, 
makes it indeed a very attractive option 
to consider11 It can be used for between 
5 and 10 years, and its effectiveness is 
not influenced by patient compliance or 
the lack thereof.
Tubal ligation
This remains a very effective means of 
contraception for the perimenopausal 
woman and in many countries around 
the world it is indeed the most common 
form of contraception. Laparoscopic 
tubal ligation or a procedure performed 
by mini laparotomy offer women, be-
sides the anaesthetic risk, a safe method 
of permanent contraception with, usu-
ally, a very low complication rate. Similar 
protection against ovarian cancer has 
been reported for tubal ligation and 
combined oral contraceptives.12 Tubal 
ligation does not have any effect on the 
menstrual cycle. This method is an ideal 
option for women at the beginning of the 
perimenopausal transitional period, for 
those in whom compliance with pill tak-
ing is a problem and for women where 
other forms of contraception are contra-
indicated.
Other options
All other forms of available contracep-
tion can also be used by perimeno-
pausal women. Periodic abstinence is 
not advisable as one of the features of 
the perimenopuasal transitional period 
is chronic anovulation which makes the 
prediction of time of ovulation virtually 
impossible. Barrier contraception in the 
form of male or female condoms is also 
an option that can be considered, espe-
cially when protection against sexually 
transmitted diseases is required. The 
decreased fecundity in the perimeno-
pausal years will probably contribute 
to an increase in the effectiveness of 
barrier contraception. Vasectomy for 
the male partner of the perimenopausal 
woman should always be discussed as 
an option, especially in patients with 
contra-indications for most other forms 
of contraception and where there is a 
risk for a surgical procedure.
Conclusion
Contraception in the perimenopausal 
transition years is a very important as-
pect of women’s health, and it is the re-
sponsibility of all health care workers to 
be able to discuss and render adequate 
counselling in this regard. Failure to do 
so can have serious health and mental 
consequences caused by unplanned 
pregnancies. There are a number of 
safe and effective options that one can 
offer these women. Most of these meth-
ods also have beneficial non-contracep-
tive properties. A complete history and 
physical examination is mandatory in 
order to identify the most suitable form 
of contraception for every individual 
woman.. 
See CPD Questionnaire, page 41
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